Market Cap: $37.27B
BI
Biogen Inc.
BIIB
NASDAQ (NASDAQ Global Select)USD
Market Cap: $37.27B
Biogen (Ticker: BIIB) is currently undergoing a significant transformation in its strategic approach, focusing on innovative therapies in the biopharmaceutical market. A Shift in Focus Moving away fro…
Biogen Inc. (Ticker: BIIB) makes headlines with its strategic acquisition of RayThera Inc., a move that underscores its commitment to expanding its neurological treatment portfolio. Recently announced…
Biogen Inc. (Ticker: BIIB) has recently achieved a significant milestone by receiving the FDA Breakthrough Therapy Designation for salanersen, an investigational treatment designed for patients with s…
Biogen Inc (Ticker: BIIB) is navigating a pivotal moment in its quest to treat Alzheimer’s disease, as the U.S. Food and Drug Administration (FDA) has delayed its review of a key treatment. The compan…
Biogen Inc. (Ticker: BIIB) is actively navigating the extended FDA review process for its Alzheimer’s treatment, LEQEMBI IQLIK, which could have significant implications for the company’s future in ne…
Biogen's recent acquisition of felzartamab from TJ Biopharma marks a significant milestone in its strategic expansion within the immunology sector, particularly in the Greater China region. The deal,…
Biogen's SPINRAZA™ High Dose Regimen Approval Marks a Milestone for SMA Treatment In a significant development for the spinal muscular atrophy (SMA) community, Biogen receives FDA approval for the Hig…
Analyst Chorus Narrows on Biogen's Strategic Crossroads Pipeline, Regulation and Commercial Execution Take Center Stage Biogen (NASDAQ:BIIB) is facing intensified scrutiny as 21 financial analysts pub…
Biotech spotlight: Biogen’s earnings set to frame sector conversation Biogen is reporting quarterly results on Friday morning and the company’s update is taking on outsized importance for the biotech…
Empowering Lupus Patients Through Innovative Engagement Initiatives Proximity Health Solutions, in collaboration with Biogen, gains recognition for its groundbreaking initiative "Better Together: Shar…
Biogen's Strategic Positioning Amidst Analyst Scrutiny In the latest quarterly evaluation, Biogen garners attention from nine analysts, each presenting a mix of ratings that reflect a spectrum of conf…
Johnson & Johnson's Advancements in Lupus Treatment: A Step Toward Innovative Solutions Johnson & Johnson (NYSE: JNJ) makes headlines with the topline results from its Phase 2b JASMINE study, which ev…
Biogen's Position in the Evolving Autoimmune Disease Landscape Biogen faces a critical juncture in the biopharmaceutical industry as it navigates the complexities of autoimmune disease treatment. With…
Biogen's Strategic Focus on Innovation in Neurodegenerative Diseases Biogen, a leading biotechnology company, remains at the forefront of research and development in neurodegenerative diseases, a sect…
### Biogen’s Strategic Positioning in the Evolving Pharmaceutical Landscape Biogen, a leader in neuroscience, is navigating the complexities of the pharmaceutical industry amidst a landscape character…
Biogen Faces Growing Bearish Sentiment Amid Increased Short Interest Biogen Inc. experiences a significant uptick in short interest, which rises by 10.35% since the last reporting period. Currently, 6…
Biogen Faces Rising Bearish Sentiment Amid Increased Short Interest Biogen Inc. is currently experiencing a significant uptick in short interest, which has risen by 10.35% since the last report. As of…
Breakthrough Findings in Alzheimer's Treatment: LEQEMBI's Long-Term Impact At the recent 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, Biogen Inc. and Eisai Co., Ltd. unveil promising…
Biogen and Eisai Pursue New Administration Route for Alzheimer’s Treatment Biogen Inc. and its partner Eisai Co., Ltd. take a significant step forward in the treatment of Alzheimer’s disease with the…
Biogen's Position in Alzheimer's Research Strengthened Amid Competitor Setbacks Biogen Inc. is capitalizing on the recent setbacks faced by competitors in the Alzheimer's treatment space, particularly…
Strategic Insights into Biogen's Market Dynamics Recent trends in Biogen's trading activity reveal a notable shift in market sentiment, particularly among high-profile investors. Analysis from Benzing…
Biogen's Strategic Innovations: A Beacon in Neurology Biogen is currently making significant strides in the biotechnology sector, particularly in the field of neurology. The company focuses on develop…
FDA Leadership Shakeup: Implications for Drug Safety and Regulatory Integrity The recent resignation of George Tidmarsh, head of the FDA's drug center, raises significant questions about the integrity…
Biogen's Strategic Positioning Amid Market Dynamics Biogen remains at the forefront of the biotechnology sector, particularly focusing on the treatment of neurological diseases. As the company navigat…
Biogen's Upcoming Earnings Report: A Focus on Innovation and Pipeline Development As Biogen prepares to release its quarterly earnings on October 30, 2025, the biotechnology company stands at a pivota…